Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-PRISM
NCT05469893Phase 2Recruiting
- Start
- Aug 2022
- Primary completion
- Jul 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in smoldering multiple myeloma (SMM). Started Aug 2022; status: recruiting.
02
Drugs
teclistamab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05469893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469893.